Detalhe da pesquisa
1.
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Lancet
; 401(10389): 1655-1668, 2023 05 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37068504
2.
Zolbetuximab plus chemotherapy for locally advanced unresectable or metastatic stomach or gastroesophageal junction cancers: a plain language summary.
Future Oncol
; : 1-17, 2024 May 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38861294
3.
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Nat Med
; 29(8): 2133-2141, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37524953